Weighing the Evidence on Rybrevant
- Rybrevant is a lung cancer drug given by IV that blocks growth signals cancer cells rely on. How well it works — and what it costs in side effects — depends on your specific gene mutation.
- For patients with a specific lung cancer gene mutation called an exon 20 insertion (a change in the EGFR gene that’s historically been hard to treat), PAPILLON found Rybrevant plus chemo extended survival by about 6.5 months (34.3 vs. 27.9 months) — the longest survival seen yet in this group, though not statistically definitive since many chemo-only patients later crossed over to Rybrevant, blurring the comparison.
- For exon 19 or L858R mutations, the MARIPOSA study found that Rybrevant plus Lazcluze controlled cancer longer and improved 3-year survival than Tagrisso, the current standard—but with more side effects and treatment burden.
- A separate study, COPERNICUS, is testing an injectable version of Rybrevant for easier administration.
- Rybrevant shows promise, but the trade-offs and strength of evidence vary by mutation type. Worth discussing with your oncologist.
The two updates come from different trials and apply to different patients. How well Rybrevant works, and what side effects it causes, depends on which EGFR gene mutation a person’s tumor carries.
Read MorePAPILLON: A Numerical Difference With an Important Qualification
PAPILLON included 308 untreated patients with advanced lung cancer carrying an exon 20 insertion. They received intravenous Rybrevant with two chemotherapy drugs, carboplatin and pemetrexed, or chemotherapy alone.After a median follow-up of 48.6 months, median overall survival in this untreated, advanced exon 20 insertion population was 34.3 months with the Rybrevant combination and 27.9 months with chemotherapy. “Median” is the point when half the group was still alive; it does not predict an individual’s survival.
The 6.4-month difference was not statistically significant in the standard randomized analysis, which kept patients in their original groups. In practical terms, this means the trial cannot rule out the possibility that chance, rather than a real drug effect, drove the difference.
Crossover complicated the analysis: 97 of 128 chemotherapy patients whose cancer progressed, or 76%, later received Rybrevant. Giving the active drug to much of the comparison group makes a survival difference harder to detect.
A planned analysis estimating survival without crossover suggested a 43% lower risk of death with the Rybrevant combination. Crossover may therefore have concealed part of the benefit, but this estimate relies on assumptions and does not replace the nonsignificant randomized result.
Expert Resources for Lung Cancer Patients
- For Lung Cancer Patients With The EGFR Mutation: The Benefit of The Drug TAGRISSO Plus Chemotherapy
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A ‘Practice Changing’ Trial
- Targeted Therapy In A Shot: New Approval for EGFR-Mutated Lung Cancer Can Improve Day-To-Day Life For Patients
- New Drug Rybrevant Extends Life In Hard-To-Treat Non-Small Cell Lung Cancer
- Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval
Is Rybrevant Better Than Tagrisso?
For an exon 20 insertion, that is not the relevant comparison: Tagrisso (osimertinib) is not FDA-approved specifically for this mutation.
For untreated advanced cancer with an exon 19 deletion or L858R mutation, the MARIPOSA trial compared intravenous Rybrevant plus the pill Lazcluze (lazertinib) with Tagrisso alone. The combination controlled the cancer for a median of 23.7 months (progression-free survival), compared with 16.6 months with Tagrisso. Separately, looking at overall survival, the combination reduced the risk of death by 25%, and three-year survival was 60% versus 51%.
By these measures, Rybrevant plus Lazcluze performed better. Grade 3 or higher side effects – meaning severe or more serious events – occurred in 80% of patients, compared with 52% receiving Tagrisso. Tagrisso is one daily pill; the combination requires clinic treatment and monitoring. The choice balances effectiveness, side effects, clotting or bleeding risk, and convenience.
Tagrisso plus chemotherapy is also approved but has not been compared directly with Rybrevant plus Lazcluze.
COPERNICUS: A Shot and Proactive Side-Effect Care
COPERNICUS studied Rybrevant Faspro — “Faspro” denotes the under-the-skin (subcutaneous) formulation, as opposed to the standard intravenous version — plus Lazcluze (lazertinib) in patients with exon 19 deletion or L858R disease. After four weekly loading doses, Rybrevant was given every four weeks and took five minutes to inject.
COPERNICUS did not include a Tagrisso comparison group, so it cannot show that under-the-skin Rybrevant is safer or more effective than existing options. It examined treatment delivery and side-effect prevention only — the figures below describe what happened on this regimen, not how it compares to alternatives.
Patients received preventive blood-thinning medication for four months and skin care, including antibiotics, moisturizer, and nail care. Among 214 patients followed for 8.3 months, 25% developed a rash, about 3% had injection-related reactions, and about 3% developed a blood clot in a vein. Most side effects were mild or moderate, but 8% stopped treatment because of side effects.
A separate estimate of less than 1% applied only to stopping Rybrevant because of rash or blood clots specifically. It should not be confused with the 8% figure.
Without a Tagrisso group, COPERNICUS cannot show that under-the-skin Rybrevant is safer or more effective. It examined treatment delivery and side-effect prevention. The U.S. Food and Drug Administration has approved both Rybrevant Faspro and monthly dosing.
Questions to Ask Your Doctor
- What is my exact EGFR mutation?
- Which trial applies to my cancer?
- How do expected benefits and side effects compare?
- Would I need blood-thinning medication and skin care?
Learn more about SurvivorNet's rigorous medical review process.
